Genprex, Inc.
Close on Oct 19, 2026
- Market cap
- $974.71K
- P/E (TTM)
- –
- Dividend yield
- –
About Genprex
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology firm focused on developing gene therapies for oncology and diabetes. Its oncology pipeline relies on its proprietary ONCOPREX Delivery System, an intravenous, non-viral nanoparticle platform that carries tumor suppressor genes directly to cancer cells. The lead drug candidate, REQORSA (quaratusugene ozeplasmid), administers the TUSC2 gene and is under clinical investigation in combination with standard therapies for non-small cell lung cancer and small cell lung cancer. In diabetes, the company develops GPX-002, a preclinical candidate engineered to restore insulin generation in type 1 and type 2 diabetes. Its potential end users are patients suffering from advanced lung cancers and diabetes.
The business conducts its research and clinical operations within the United States. Its clinical pipeline includes trials across multiple medical facilities, with a planned phase 2 expansion study intended to enroll patients across 10 to 15 domestic sites. Preclinical programs and licensed technologies are researched in collaboration with academic centers, including The University of Texas MD Anderson Cancer Center and the University of Pittsburgh.
Summary of the business section of Genprex's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Genprex, Inc.
- Headquarters
- Austin, TX
- Address
- 3300 Bee Cave Road Suite 650-227 78746
- Phone
- (512) 537-7997
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- GNPX
- Exchange
- Nasdaq
- IPO date
- Oct 13, 2017
- Shares outstanding
- 1M, Aug 10, 2026
- Public float
- $7.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-22 reverse, Jul 16, 2026; 1-for-50 reverse, Nov 14, 2025; 1-for-50 reverse, Oct 21, 2025; 1-for-40 reverse, Apr 1, 2024; 1-for-40 reverse, Feb 2, 2024; 34-for-1, Apr 17, 2018
- SEC CIK
- 1595248
- CUSIP
- 372446401
- ISIN
- US3724464017
- LEI
- 549300KS9771JZ234890
- EIN
- 90-0772347
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan M. Confer | President, CEO and CFO, Director | 36,331 |
| Mark Stanley Berger | Chief Medical Officer | 21,692 |
| Brent M. Longnecker | Director | 9,157 |
| William R. Wilson Jr. | Director | 9,157 |
| Toscano Jose Antonio Moreno | Director | 9,157 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Rodney Varner | $0 | $0 | $688.60K | $-96 | – |
| FY2025 Ryan MConfer | $728.87K | $906.31K | $688.60K | $-96 | – |
| FY2024 Rodney Varner | $254.74K | $343.07K | $500.42K | $-91 | – |
| FY2024 Ryan MConfer | $541.57K | $588.70K | $500.42K | $-91 | – |
| FY2023 Rodney Varner | $1.68M | $909.63K | $940.19K | $-84 | – |
| FY2023 Ryan MConfer | $0 | $0 | $940.19K | $-84 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 15, 2026, we had 13 total employees, all of which were full-time.”
Corporate history
Events identified from SEC filings